Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02668705 · ClinicalTrials.gov registry record · NA
Agent-Enhanced Document Explanation
A NA study, sponsored by Boston Medical Center.
- Terminated
- Registry status
- NA
- Development phase
- 101
- Enrollment target
NCT02668705: Clinical Trial NA study, sponsored by Boston Medical Center.
NCT02668705 is a NA study that was terminated before completion, run by Boston Medical Center. The registered enrollment target is 101 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02668705, a NA study, was terminated before completion, sponsored by Boston Medical Center.
- TERMINATED
- Registry status
- NA
- Development phase
- 101 participants
- Enrollment target
Study Summary
Both the main and sub-studies will investigate how consent forms and other health care documents are explained to patients. The findings will be used to create a computer program that can successfully explain consent and other health-related forms to individuals who have difficulty reading and understanding consent forms on their own as a supplement to the normal consent process done in research settings.
Primary Outcome
as determined by verbally administering the Brief Informed Consent Evaluation Protocol (BICEP) instrument.
Interventions
- OTHER Embodied Conversational Agent
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 101 participants |
| Start Date | 2015-09 |
| Est. Completion | 2016-09 |
| Phase | NA |
Why NCT02668705 stopped before completion
NCT02668705 is an interventional study that assigns participants to a tested intervention. The registered 101 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 1 intervention - of which Embodied Conversational Agent is the first listed.
NCT02668705 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02668705 about?
NCT02668705 is a clinical study titled "Agent-Enhanced Document Explanation". Both the main and sub-studies will investigate how consent forms and other health care documents are explained to patients. The findings will be used to create a computer program that can successfully explain consent and other health-related forms to individuals who have difficulty reading and under...
What is the current status of trial NCT02668705?
This trial is currently terminated. It is a NA study. The enrollment target is 101 participants. The study started on 2015-09. Estimated completion is 2016-09.
What interventions are being tested in trial NCT02668705?
The interventions under investigation include: Embodied Conversational Agent (OTHER).
Who is sponsoring clinical trial NCT02668705?
This trial is sponsored by Boston Medical Center, which has 253 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02668705's enrollment target sits among peer trials
101 840th of 2000 higher than 1,161 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04033497 · 101 participants · NA
Treatment Response Assessment Maps to Delineate Necrosis From Tumor After Stereotactic Radiation in Brain Metastases
- NCT05111574 · 101 participants · Phase 2
Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery
- NCT05984680 · 101 participants
COPD Care Pathway Among Patients With Cancer
- NCT06266299 · 101 participants · Phase 1
A Study of KK2269 in Adult Participants With Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia